GlassScriptPhysician profile
Leighla A Smith
NPI 1912566522
$1,154.37
in general payments reported to CMS, 2019-2025
22 companies · $543 in 2025
The $543 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $129 · 2024: $482 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.31 | 2024-2025 | |
| Lilly USA, LLC | $132.88 | 2023-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $87.49 | 2024-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $82.22 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $81.01 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $52.56 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $48.48 | 2024-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $36.86 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $30.62 | 2025 | Fanapt |
| Exact Sciences Corporation | $29.42 | 2024-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $29.40 | 2025 | Vivitrol |
| Nevro Corp. | $29.23 | 2024 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.24 | 2025 | Caplyta |
| Microtransponder, INC. | $24.35 | 2024 | |
| Grifols USA, LLC | $23.90 | 2024 | Prolastin-C Liquid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $22.90 | 2024 | Yupelri |
| Pfizer INC. | $20.65 | 2024 | |
| Eisai INC. | $17.45 | 2025 | |
| Supernus Pharmaceuticals, INC. | $17.10 | 2024 | Qelbree |
| Owp Pharmaceuticals, INC. | $16.77 | 2024 | Subvenite |
| Aimmune Therapeutics, INC. | $15.07 | 2025 | Zenpep |
| Kowa Pharmaceuticals America, INC. | $13.46 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leighla Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.